Target concentration intervention (TCI) is proposed as an alternative conceptual strategy to therapeutic drug monitoring (TDM). It is argued that the idea of a therapeutic range has limited the interpretation of measured drug concentrations and diminished the anticipated clinical benefit to patients by use of an oversimplified pharmacodynamic model. TCI on the other hand embraces pharmacokinetic and pharmacodynamic concepts and uses the idea of a target effect and associated target concentration to make rational individual dose decisions.
framework for using all available information about the Target Concentration Intervention (TCI) and patient and the disease in order to interpret effect and Therapeutic Drug Monitoring (TDM) concentration observations. Successful interpretation will lead to a positive decision to select the best dose to The Y2K problem achieve the desired therapeutic effect. This is target In her lead article for this series Shenfield [1] seeks a role concentration intervention (TCI) [5] . for therapeutic drug monitoring (TDM) beyond the year Target concentration intervention is a treatment strat-2000. Her discussion and that in ensuing articles [2] [3] [4] egy. As such it is comparable with other forms of focus almost exclusively on the measurement and treatment and can be evaluated using broadly similar interpretation of drug concentrations in relation to a techniques (vide infra). TDM has rarely been evaluated as 'therapeutic range'. I contend that 'therapeutic drug a treatment strategy. Most commonly forecasting methodmonitoring' and 'the therapeutic range' are the year 2000 ologies are compared to see if they can predict future (Y2K) problem for clinical pharmacologists. The Y2K concentrations (or effects) but to my knowledge no problem arose from a limited perspective on how to formal tests of alternative therapeutic ranges have ever represent dates in computer storage. Only the year index been performed. within a century is stored and it is assumed that the century and millenium are understood by default. TDM Target concentration and therapeutic range manifests a limited perspective by using concentrations with the unstated assumption that the effects arising from Sheiner & Tozer [6] proposed the target concentration those concentrations are understood by default. The strategy (TCS) as an algorithm for rational dose individtherapeutic range limits attention to concentrations within ualization but this idea has rarely been recognized. The empirically chosen bounds.
essential feature of the algorithm is to use a target concentration rather than a range. The goal is to achieve this target using initial doses based on typical pharmacoTarget concentration intervention kinetic parameters for the individual predicted from It is time to pay attention to the concentration effect patient specific factors (covariates) such as body size and relationship and to think about the broader strategy of renal function. Drug concentration measurements are how to individualize drug treatment with the aid of drug used solely to individualize the PK parameters in order concentration measurements. TDM has become tedium to predict future dosing. TCS does not aim to have the because of its focus on the passive concept of 'monitoring' measured concentration equal to the target concentration. and its failure to explicitly take drug effects into account. This is a key distinction from TDM which aims to have The synthesis of pharmacokinetic (PK) and pharmacothe measured concentration within the therapeutic range. dynamic concepts (PD) provides a sound intellectual TCS explicitly uses a PK model to understand what makes the patient an individual while TDM offers no The therapeutic range concept suffers from two to achieve that effect. The target effect may vary with time as the disease state changes. The time course of strategic deficiencies. First the idea of a range introduces uncertainty into exactly how to prescribe the desired disease progress (disease kinetics) has had little quantitative study but it is just as important a part of the process as dose. It is of course impossible to administer simultaneously a range of doses yet a range is the inevitable the pharmacodynamic and pharmacokinetic aspects [8] . consequence of aiming for a range of concentrations and the prescriber must use some process to choose a specific Target effect dose. TDM and the therapeutic range give no guidance
What do we know? for making this choice.
On the other hand, the target concentration is directly Table 2 illustrates the rather sparse information we have linked to a specific dose for an individual -not a range of about the pharmacodynamics of drugs which are comdoses. Dose predictions are usually simple applications of monly associated with TDM. Only theophylline has been elementary PK principles [7] (Table 1 ), e.g. if the target is sufficiently characterized to predict the concentration the steady state average concentration then the dose rate effect relationship. Note that E max for theophylline is simply the product of the individual estimate of clearance reflects the maximum improvement from baseline [11] . and the target concentration. Aiming for a specific target If E max was achieved, the actual PEFR would be the provides unambiguous guidance for the prescriber. The sum of the baseline PEFR and E max . Incorporation of a target concentration is separated from the concentrationdisease progress model gives a more complete picture effect relationship. The intellectual process required to [10] at different times and concentrations. choose a target concentration is independent of any consideration of pharmacokinetics. Selection of a target How can we find out? concentration requires an understanding of the concentration-effect relationship, i.e. pharmacodynamics, for both Defining the concentration effect relationship using clinically relevant effects is challenging. It has become desired and undesired effects. The target concentration is chosen to optimize the balance between these effects. increasingly common to describe the clinical pharmacology of a drug based on the use of a biomarker and The second deficiency of the therapeutic range concept is the implicit assumption that all concentrations within while this may be helpful for guiding drug development the pharmacodynamics of a clinical endpoint are needed the range are equally desirable. This assumption implies a 3 step concentration effect relationship. Below the to apply TCI. The population modelling approach has been used to understand concentration effect relationships lower end of the range the patient will get no benefit, anywhere within the range the patient will be OK and and can be used with a variety of measures of clinical effect [12] . The easiest to model are those based on a above the upper end the patient will experience unacceptable toxicity. This is patently naïve but is the apparent continuous measure of effect, e.g. PEFR. However, clinical endpoints are more commonly categorical, e.g. model used by TDM practitioners today.
cure of infection, prevention of organ rejection, or perhaps based on frequency of an event, e.g. seizure PK, PD and disease progress frequency. Methodology now exists that can incorporate a common pharmacokinetic-pharmacodynamic approach The full target concentration strategy requires the selection of a target effect then the target concentration to all these measures [13] . Table 3 are mainly percentage coefficient of variation for variability in guesses based on the usual therapeutic range. The clearance is reported as 70% this implies a total variance theophylline target concentration (10 mg l −1 ) has been of a lognormal distribution of about 0.5 (i.e. 0.7 2 ). This tested prospectively and shown to produce a useful is the population parameter variability (PPV) which is change in peak expiratory flow rate with a reduced risk the sum of between subject variability (BSV) and within of nausea and vomiting compared with a target of subject variability (WSV). For practical reasons, the 20 mg l −1 [9] . within subject component is usually estimated as the If an individual target effect (TE) is known the target interoccasion variability (IOV) [15] . This can be thought concentration (TC) required is predictable from:
of as a description of the likely within subject random variation in clearance from the time of estimating TC= EC 50 ΩTE E max −TE clearance from a measured concentration using TCI, until the next occasion or dose, when the target effect from the new dose prediction is expected. WSV for e.g. to achieve a TE of 200 l min −1 increase in PEFR clearance is a measure of the minimum variability in for theophylline a target concentration of 15 mg l −1 is average steady state concentration that can be achieved required.
by using TCI. If the variance associated with WSV is 0.1 then BSV must be 0.4 (PPV=0.5=WSV+BSV). These How can we find out?
correspond to a CV% of 31% (square root of WSV) within individuals and 63% (square root of BSV) between The estimation of pharmacokinetic parameters for TCI individuals. The steady state concentration in an individual focuses primarily on clearance and volume of distribution.
will therefore vary by about 31% from one occasion to The population approach to pharmacokinetics is the another (BSV) in contrast to a 70% variation (total) if natural method for describing these parameters and comparing the concentrations from different individuals. important covariate influences. An automated approach On average, TCI can expect to achieve target effects by to discovering covariate models has been described learning about and accounting for the way an individual recently [14] .
is systematically different (BSV) from another apparently similar person. It can not influence WSV. If the acceptable Interpreting concentrations and effects variability in concentration for safe and effective use of a drug is greater than PPV then TCI is unnecessary. If Sources of variability acceptable variability is less than WSV then TCI cannot When concentrations are measured in order to guide make use of the drug safe and effective. TCI has its place future dosing there is an implicit assumption that the way when acceptable variability lies between PPV and WSV. the patient differs from an average patient is captured in this measurement, and that the patient will remain Bayesian forecasting predictably different in the future. There are two sources of variability in PKPD parameters that need to be
The key feature, in the clinical setting, of pharmacokinetic interpretation of drug concentrations is the very limited considered when deciding if concentration or effect measurements can help with predicting future dose needs. number of observations. Typically only one concentration is available and even with the simplest of models there factor that may influence the power of an RCCT but the intensity of this process may vary from a single will be at least two parameters (clearance and volume of distribution) to be estimated and of course there will be measurement to intensive sampling profiles. The latter has been used in what might arguably be cited as the some inevitable measurement error and model misspecification. The best approach to extract useful information most impressive application of TCI. The 5 year survival rate in acute lymphoblastic leukaemia increased from from such limited data is to use a Bayesian estimation method for the parameters. Programs are quite widely 66% to 76% when TCI was applied to methotrexate treatment [23] . This is better than any new single drug available for this purpose and have been known for a long time to be at least as good as an experienced cancer treatment that has been developed in recent years. The methotrexate study compared a TCI approach, with clinician in terms of the precision of achieving the target concentration [16, 17] . The essential information required intensive sampling feedback, to one based on size adjusted dosing. The target concentration was based on the for Bayesian estimation is usually provided in the output of a population analysis, i.e. the population values of the maximum tolerated value in earlier tolerability studies. parameters, covariate models which predict typical values from the population prior to starting treatment and Conclusion estimates of the variability in the typical parameters and the measurement and model misspecification error.
The year 2000 is nigh. The challenge for clinical pharmacology is to devise and execute RCCTs that will test alternate target concentration strategies and move Trial designs for TCI beyond the methodological issues of dose adjustment The target concentration approach lends itself to evalualgorithms and the blinkered viewpoint of the theraation by comparing the clinical outcome associated with peutic range. different target concentrations. Note that information about the target effect and corresponding target concen- Two target concentrations of theophylline (10 and 
